CELSION CORPORATION (AMEX: CLN) today reported that it had signed an option to license worldwide rights to a novel peptide ligand for targeting drug delivery vehicles to cancer cells. The option gives Celsion the exclusive rights to perform scientific and intellectual property due diligence on this ligand. Additionally the option provides Celsion an exclusive license negotiation period. As part of the option agreement, Celsion has filed patent applications covering the ligand and its use as a targeting agent.